GB201510684D0 - Gene signatures predictive of metastatic disease - Google Patents

Gene signatures predictive of metastatic disease

Info

Publication number
GB201510684D0
GB201510684D0 GBGB1510684.2A GB201510684A GB201510684D0 GB 201510684 D0 GB201510684 D0 GB 201510684D0 GB 201510684 A GB201510684 A GB 201510684A GB 201510684 D0 GB201510684 D0 GB 201510684D0
Authority
GB
United Kingdom
Prior art keywords
metastatic disease
gene signatures
signatures predictive
predictive
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1510684.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Diagnostics Ltd
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Priority to GBGB1510684.2A priority Critical patent/GB201510684D0/en
Publication of GB201510684D0 publication Critical patent/GB201510684D0/en
Priority to PCT/GB2016/051825 priority patent/WO2016203262A2/en
Priority to CA2989388A priority patent/CA2989388A1/en
Priority to EP16731299.0A priority patent/EP3310927B1/en
Priority to HK18105968.7A priority patent/HK1246367A1/zh
Priority to JP2017565108A priority patent/JP2018527886A/ja
Priority to US15/736,667 priority patent/US20210254166A1/en
Priority to CN201680045157.3A priority patent/CN108513587A/zh
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1510684.2A 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease Ceased GB201510684D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1510684.2A GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease
PCT/GB2016/051825 WO2016203262A2 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease
CA2989388A CA2989388A1 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease
EP16731299.0A EP3310927B1 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease
HK18105968.7A HK1246367A1 (zh) 2015-06-17 2016-06-17 转移性疾病的基因标记预测
JP2017565108A JP2018527886A (ja) 2015-06-17 2016-06-17 転移性疾患の予測的遺伝子シグネチャー
US15/736,667 US20210254166A1 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease
CN201680045157.3A CN108513587A (zh) 2015-06-17 2016-06-17 对转移性疾病具有预测性的基因标签

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1510684.2A GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease

Publications (1)

Publication Number Publication Date
GB201510684D0 true GB201510684D0 (en) 2015-08-05

Family

ID=53784091

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1510684.2A Ceased GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease

Country Status (8)

Country Link
US (1) US20210254166A1 (enExample)
EP (1) EP3310927B1 (enExample)
JP (1) JP2018527886A (enExample)
CN (1) CN108513587A (enExample)
CA (1) CA2989388A1 (enExample)
GB (1) GB201510684D0 (enExample)
HK (1) HK1246367A1 (enExample)
WO (1) WO2016203262A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11341138B2 (en) * 2017-12-06 2022-05-24 International Business Machines Corporation Method and system for query performance prediction
GB201901439D0 (en) * 2019-02-01 2019-03-27 Univ London Method of predicting survival rates for cancer patients
GB201903015D0 (en) * 2019-03-08 2019-04-17 Univ Edinburgh Macrophage expression in breast cancer
GB201903014D0 (en) * 2019-03-06 2019-04-17 Univ Edinburgh Macrophage markers in cancer
CA3168490A1 (en) * 2020-01-21 2021-07-29 Miha STAJDOHAR Evaluating the robustness and transferability of predictive signatures across molecular biomarker datasets
EP4133491A1 (en) 2020-04-09 2023-02-15 Tempus Labs, Inc. Predicting likelihood and site of metastasis from patient records
CN116096899A (zh) 2020-06-29 2023-05-09 Ionis制药公司 调节plp1的化合物和方法
US20230390367A1 (en) * 2020-10-19 2023-12-07 Temple University - Of The Commonwealth System Of Higher Education Genetic approach to suppress coronaviruses
CN120197220B (zh) * 2025-05-23 2025-08-01 华信咨询设计研究院有限公司 一种基于数据集中度的数据风险评估方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
CA1340843C (en) 1987-07-31 1999-12-07 J. Lawrence Burg Selective amplification of target polynucleotide sequences
KR0148265B1 (ko) 1988-12-16 1998-10-15 에프.지이.엠 헤르만스 자가-지속 서열 복제 시스템
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
EP1474528A4 (en) * 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS FOR DIAGNOSING PROSTATE CANCER, COMPOSITIONS AND METHODS FOR SCREENING PROSTATE CANCER MODULATORS
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
EP1604014A4 (en) * 2003-03-20 2008-03-26 Dana Farber Cancer Inst Inc GENE EXPRESSION IN BREAST CANCER
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
AU2005300688B2 (en) 2004-11-03 2012-02-02 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
US20140018249A1 (en) * 2006-07-26 2014-01-16 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
JP2010535529A (ja) 2007-08-13 2010-11-25 アルマック ダイアグノスティックス リミテッド マイクロアレイ製造用３’ベースシークエンシング手法
WO2010068839A2 (en) * 2008-12-11 2010-06-17 The Regents Of The University Of California Membrane compositions and methods for making and using them
CA2782620A1 (en) * 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
EP2709614A4 (en) * 2011-05-17 2015-04-15 Takeda Pharmaceutical PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER
US20150218646A1 (en) * 2012-07-20 2015-08-06 Diagnocure Inc Methods, kits and compositions for providing a clinical assessment of prostate cancer

Also Published As

Publication number Publication date
WO2016203262A3 (en) 2017-01-26
EP3310927A2 (en) 2018-04-25
EP3310927B1 (en) 2021-05-19
CA2989388A1 (en) 2016-12-22
CN108513587A (zh) 2018-09-07
JP2018527886A (ja) 2018-09-27
HK1246367A1 (zh) 2018-09-07
US20210254166A1 (en) 2021-08-19
WO2016203262A2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
IL304084B1 (en) Gene healing
IL255729A (en) Methods for predicting pathogenicity of variant gene sequences
ZA201701916B (en) High-throughput nucleotide library sequencing
ZA201701246B (en) Synthesis of dna
LT3368678T (lt) Genetinis konstruktas
SG11201610168YA (en) Nucleic acid synthesis techniques
GB201510684D0 (en) Gene signatures predictive of metastatic disease
GB201805452D0 (en) Predicting disease burden from genome variants
LT3662910T (lt) Trail geno indukcijai skirtas farmakoforas
IL255515A (en) Identification of genetic changes
IL257831B2 (en) Diplosporic garden
GB201407322D0 (en) Gene therapy
IL249254B (en) Gene expression system
IL257500A (en) Altered cullin1 gene
GB201517241D0 (en) DNA modification
GB201614153D0 (en) Microfluid arrangements
SG11201609108TA (en) Antibody gene expression-secretion system
GB201608944D0 (en) Gene Tharapy
SG10201912789UA (en) Determination of mtrnr1 gene mutation
GB201503969D0 (en) Reporter gene assay
AU2014901825A0 (en) Biomarker of Disease
AU2016901024A0 (en) Biomarker of disease
GB201704466D0 (en) Behavioural assay
GB201506520D0 (en) Planar member formation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)